<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01820728</url>
  </required_header>
  <id_info>
    <org_study_id>DA3801_CA_III (Version 4.0)</org_study_id>
    <nct_id>NCT01820728</nct_id>
  </id_info>
  <brief_title>A Phase III Clinical Study to Compare the Efficacy and Safety of DA-3801 and That of Gonal-F®</brief_title>
  <official_title>A Phase III Clinical Study for the Comparison Evaluation of DA-3801 and Gonal-F® in Infertile Female Patients With Chronic Anovulation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III comparative study to evaluate the effectiveness and safety of DA-3801 in
      treatment of the patients with WHO Group II anovulatory infertility failing to clomiphene
      citrate treatment. The study is conducted with following methods: open label,
      active-controlled, randomized, parallel group, comparative.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The ovulation rate after 3 cycles of the injection</measure>
    <time_frame>5 weeks maximum</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose used, IU (International Unit)</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stimulation, days</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Threshold dose, IU</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of follicles</measure>
    <time_frame>5 weeks</time_frame>
    <description>Counter the number of follicles which are 12 mm, 15 mm, 18 mm in diameter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Infertility</condition>
  <condition>Anovulation</condition>
  <arm_group>
    <arm_group_label>DA-3801 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recominant human follicle stimulating hormone 75 IU/day is injected for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonal-F®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>75 IU/day is injected for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-3801 Injection</intervention_name>
    <arm_group_label>DA-3801 injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonal-F®</intervention_name>
    <arm_group_label>Gonal-F®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  WHO group II

          -  Clomiphene citrate resistance

          -  BMI: 17~29 kg/m^2

          -  Irregular menstrual cycle

          -  Normal blood concentration of FSH, E2, prolactin and TSH

        Exclusion Criteria:

          -  Uncontrolled endocrine disease

          -  Ovarian cystic tumor which are NOT related to PCOS

          -  Severe endometriosis

          -  Chronic cardiovascular disease, liver complaint
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eung Gi Min, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongguk University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chang Suk Suh, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Doo Seok Choi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chung Hoon Kim, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Min Park, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kyung Joo Hwang, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ajou University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital Institutional Review Board</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2013</study_first_posted>
  <last_update_submitted>March 26, 2013</last_update_submitted>
  <last_update_submitted_qc>March 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Anovulation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

